Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium
Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium is drawing significant interest across the industry.
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPF...
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Qualcomm announces tape-out of its 2nm semiconductor design
- Carbon Revolution Announces Receipt of Delisting Determination Letter from Nasdaq
- PM Modi's significant Malaysia visit builds on 2015 strategic upgrade: MEA Secy (East) Kumaran
- 'Virality Was Unexpected': Mona Patel Reflects On The Met Gala Debut That Changed Everything
Source: Original →